

# Summary for the QIBA CT Small Lung Nodule Profile, Version 1

## Stage 3 – Clinically Feasible

*Summary posted 8/18/2023 by RSNA Staff*

Stage 3, [Clinically Feasible](#) (formerly Technically Confirmed), was achieved by the QIBA CT Small Lung Nodule Biomarker Committee in March of 2020.

- The Biomarker Committee vote for Stage 3 (Clinically Feasible) was successful on 3/3/2020 with (Yes: 6; No: 0; abstain: 1) Majority 6 out of 7 voters.
- The CT Coordinating Committee vote passed on 3/19/2020 (Yes: 9; No: 2; abstain: 1); Majority 9 out of 16 voters.

### Participating sites:

Three clinical sites participated in evaluating the Checklist for Version 1 of the QIBA CT Small Lung Nodule Profile.

These sites were as follows:

1. The University of Milan (Italy)
2. The University of Parma (Italy)
3. Washington University – St. Peters and Barnes locations (U.S. sites)

### Observations from Dr. Mulshine, co-chair of the Small Lung Nodule Biomarker Committee, 6/1/2023:

There were no substantive difficulties in completing our conformance process with the two affiliates of Washington University and the two Italian healthcare centers. The SLN BC did review these responses and the process in the course of our Profile calls back in 2020/21. We have a cloud enabled conformance process that has now been used in over 100 participating institutions and this approach has been well received.

### Summary of site Checklist responses:

#### [University of Milan](#)

The University of Milan responded yes to all questions, except to the question for section 3.2. The folder “CT Small Lung Nodule Profile data” was unavailable, and the five pairs of nodule scans could not be accessed.

Scanners that were evaluated included:

- Somatom Force, Siemens
- Syngo.Via, Siemens

#### [University of Parma](#)

The University of Parma responded yes to all questions, except to the question for section 3.2. The folder “CT Small Lung Nodule Profile data” was unavailable, and the five pairs of nodule scans could not be accessed.

Scanners that were evaluated included:

- Somatom Edge, Siemens
- Syngo.Via, Siemens

#### [Washington University, Barnes and St. Peters sites](#)

Washington University responded yes to all Checklist questions. They completed their assessment on 6/20/2019. Details regarding scanners evaluated were not available.